triumeq
Selected indexed studies
- Triumeq--a 3-drug combination for HIV. (Med Lett Drugs Ther, 2015) [PMID:25555073]
- Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial. (Amyotroph Lateral Scler Frontotemporal Degener, 2019) [PMID:31284774]
- Intentional overdose of dolutegravir/abacavir/lamivudine (Triumeq) in a 26-year-old man. (Antivir Ther, 2018) [PMID:29533918]
_Worker-drafted node — pending editorial review._
Connections
triumeq is a side effect of
Sources
- Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. (2017) pubmed
- Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. (2020) pubmed
- Efficacy of dolutegravir plus lamivudine in treatment-naive people living with HIV without baseline drug-resistance testing available (D2ARLING): 48-week results of a phase 4, randomised, open-label, non-inferiority trial. (2025) pubmed
- Triumeq--a 3-drug combination for HIV. (2015) pubmed
- Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial. (2019) pubmed
- Intentional overdose of dolutegravir/abacavir/lamivudine (Triumeq) in a 26-year-old man. (2018) pubmed
- Trizivir. (2002) pubmed
- Case report of Triumeq (abacavir/dolutegravir/lamivudine) associated rhabdomyolysis in a human immunodeficiency virus (HIV) infected patient. (2019) pubmed
- Efficacy and safety of the switch of Triumeq(®) to generic (abacavir + lamivudine) + Tivicay(®): data at 48 weeks. (2019) pubmed
- De-simplifying single-tablet antiretroviral treatments: uptake, risks and cost savings. (2019) pubmed